Omnicare, Inc. (NYSE:OCR)

**

A stock that has been hurt by health care reform and continued cuts by patient care facilities. In particular cost cuts in Medicare Part D. All that being said, this stock has been trading below book value and has continued to throw off huge growing cash flows (trading around 10x cash flow at present). What this company will lose in reduced patient care costs, it will gain in patient volumes over the years. There is some serious future potential for Omnicare. Recent management change is a plus and the company has recently been turning lemons into lemonade (it also services these patient care facilities as far as compliance relations.) Where's the Moat? Omnicare is the largest pharma service company in NA with a huge logistics and delivery operation. They offer compliance consulting, CRO services (for all stages of drug testing), and contract based pharmacy services. They also have a wide database of patient data. In these heavily regulated environments, this company is a necessity to most patient care facilities and will continue to prosper in a sector that has potential for huge growth.